Methenamine Hippurate 1g BD

Phase 1Small molecule

UUniversity Hospitals of North Midlands NHS Trust

Methenamine Hippurate 1g BD is one of 33 small molecule programs targeting Urinary Tract Infections. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Tract InfectionsNot yet recruiting

Urinary Tract InfectionActive, not recruiting

Urinary Tract InfectionsPhase 1

Not yet recruiting

Urinary Tract InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

6 2

Cipro

Bayer

Approved

6 3

Levaquin

WWim Janssens

Approved

14 4

Ivadantin

PProcter and Gamble

Approved

12 5

Estrace

Novo Nordisk

Approved

2 6

Vesicare

Astellas

Approved

1 7

Voltaren

Novartis

Approved

1 8

Acanya

Pfizer

Approved

1 9

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

6 10

Monurol

MMeitheal

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Study completion

NCT06710899

N/ARecruiting

Urinary Tract Infection

NCT06810687

Clinical

Trials by Indication[1]

Urinary Tract Infection1 trial

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?

Recruiting·—·N/A·NCT06810687·190 enrolled

Unspecified1 trial

Vitamin C and Hiprex in rUTI

Not yet recruiting·UUniversity Hospitals of North Midlands NHS Trust·Phase 1·NCT06710899·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Methenamine Hippurate 1g BD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methenamine Hippurate 1g BD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methenamine Hippurate 1g BD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospitals of North Midlands NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospitals of North Midlands NHS Trust

Methenamine Hippurate 1g BD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Urinary Tract Infection1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News